References
- 1. T. Cabaleiro, D. Ochoa, R. López-Rodríguez, M. Román, J. Novalbos, C. Ayuso and F. Abad-Santos, Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers, Hum. Psychopharmacol. 29 (2014) 459-469; DOI: 10.1002/hup.2420.
- 2. J. L. Sun, Q. X. Chen, S. Tian, F. R. Meng, Y. Lv and G. H. Du, Absorption of risperidone polymorphs administrated orally in rats, Chin. Pharm. J. 46 (2011) 1919-1922.
- 3. T. K. Vyas, A. Shahiwala, S. Marathe and A. Misra, Intranasal drug delivery for brain targeting, Curr. Drug Deliv. 2 (2005) 165-175; DOI: 10.2174/1567201053586047.
- 4. C. R. Behl, H. K. Pimplaskar, A. P. Sileno, J. deMeireles and V. D. Romeo, Effects of physicochemical properties and other factors on systemic nasal drug delivery, Adv. Drug Deliv. Rev. 29 (1998) 89-116; DOI: doi:10.1016/S0169-409X(97)00063-X.
- 5. M. Kumar, A. Misra, A. K. Babbar, A. K. Mishra, P. Mishra and K. Pathak, Intranasal nanoemulsion based brain targeting drug delivery system of risperidone, Int. J. Pharm. 358 (2008) 285-291; DOI: 10.1016/j.ijpharm.2008.03.029.
- 6. W. N. Ma and F. G. Gu, Effect of pH on the chemical stability, solubility and oil-water partition coefficient of risperidone, Centr. South Pharm. 13 (2015) 473-476; DOI: 10.7539/j.issn.1672-2981.2015.05.006.
- 7. H. S. Mahajan, S. K. Shah and S. J. Surana, Nasal in situ gel containing hydroxy propyl β-cyclodextrin inclusion complex of arthemeter: development and in vitro evaluation, J. Incl. Phenom. Macrocycl. Chem. 70 (2011) 49-58; DOI: 10.1007/s10847-010-9861-x.
- 8. C. Tas, C. K. Ozkan, A. Savaser, Y. Ozkan, U. Tasdemir and H. Altunay, Nasal absorption of metoclopramide from different Carbopol 981 based formulations: In vitro, ex vivo and in vivo evaluation, Eur. J. Pharm. Biopharm. 64 (2006) 246-254; DOI: 10.1016/j.ejpb.2006.05.017.
- 9. F. G. Gu, F. D. Cui and Y. L. Gao, Preparation of prostaglandin E1-hydroxypropyl-β-cyclodextrin complex and its nasal delivery in rats, Int. J. Pharm. 290 (2005) 101-108; DOI: 10.1016/j. ijpharm.2004.11.021.
- 10. X. G. Jiang, J. B. Cui, X. L. Fang, Y. Wei and N. Z. Xi, Toxicity of drugs on nasal mucocilia and the method of its evaluation, Acta. Pharm. Sin. 30 (1995) 848-853; DOI: 10.3321/j.issn:0513-4870.1995.11.009.
- 11. M. Jug, I. Kos and M. Bećirević-Laćan, The pH-dependent complexation between risperidone and hydroxypropyl-β-cyclodextrin, J. Incl. Phenom. Macrocycl. Chem. 64 (2009) 163-171; DOI: 10.1007/ s10847-009-9549-2.
- 12. T. Yang, A. Hussain, J. Paulson, T. J. Abbruscato and F. Ahsan, Cyclodextrinsin nasal delivery of low molecular weight heparins: in vivo and in vitro studies, Pharm. Res. 21 (2004) 1127-1136; DOI: 10.1023/B:PHAM.0000032998.84488.7a.
- 13. E. Marttin, J. C. Vethoef and F. W. H. M. Merkus, Efficacy safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs, J. Drug Targeting 6 (1998) 17-36; DOI: 10.3109/10611869808997878.
- 14. G. Rathnam, N. Narayanan and R. Ilavarasan, Carbopol-based gels for nasal delivery of progesterone, AAPS Pharm. Sci. Tech. 9 (2008) 1078-1082; DOI: 10.1208/s12249-008-9144-7.
- 15. F. G.. Gu, D. Hao, G. D. L. Meng, C. Z. Wu and Y. Wang, Preparation of bisoprolol fumarate nasal spray and its nasal delivery in rats, Pak. J. Pharm. Sci. 28 (2015) 2173-2178.